TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05081154

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: P1012915, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: P1012915, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: P1012915, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A
Description: P1012915, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: P1013018, a nicotine pouch with 10 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: P1013018, a nicotine pouch with 10 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: P1013018, a nicotine pouch with 10 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: P1013018, a nicotine pouch with 10 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: P1013018, a nicotine pouch with 10 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: P1013018, a nicotine pouch with 10 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: P1013018, a nicotine pouch with 10 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: P1013018, a nicotine pouch with 10 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: P1013018, a nicotine pouch with 10 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: P1013018, a nicotine pouch with 10 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: P1013018, a nicotine pouch with 10 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: P1013018, a nicotine pouch with 10 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: P1013018, a nicotine pouch with 10 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B
Description: P1013018, a nicotine pouch with 10 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: P1013015, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: P1013015, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: P1013015, a nicotine pouch with 8 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: P1013015, a nicotine pouch with 8 mg nicotine
Study: NCT06409897

Intervention type: OTHER
Group type: OTHER
Intervention: Sequencial increasing of head of the bed elevation and alveolar recruitment maneuver followed by a PEEP titration with 10° of head of the elevation
Description: Patients will be sequentially positioned at 0, 10, 20, 30, and 40 degrees of head-of-bed elevation. An alveolar recruitment maneuver will be performed. For patients with body mass index ≤ 30 kg/m\^2, the maneuver will be conducted in pressure control mode, pressure control = 15 cmH2O, respiratory rate = 20 breaths per minute, and the PEEP will be increased in steps of 5 up to 30 cmH2O. For patients with body mass index \> 30, the PEEP will be increased up to 35. Then, a PEEP titration will be performed, tidal volume = 5 mL/Kg, respiratory rate = 25 breaths per minute, and the PEEP will be decreased from 24 down to 4 cmH2O in steps of 2 cmH2O with 30 seconds in each PEEP level. The PEEP titration software of Enlight 2100 will be used to determine the ideal PEEP, defined as the PEEP level with a collapse less than 5%. The alveolar recruitment maneuver will be performed again to reopen the lungs. Then, data will be collected, as with the 0 and 40-degree steps, with ideal PEEP.
Study: NCT06098105

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided transversus abdominis plane block
Description: This group will receive ultrasound-guided transversus abdominis plane block by using 1 ml/kg of bupivacaine 0.25% with a maximum volume of 20 mL as a control group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted transversus abdominis plane block
Description: Patients will receive laparoscopic-assisted transversus abdominis plane block by using 1 ml/kg of bupivacaine 0.25% with a maximum volume of 20 mL.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted intraperitoneal instillation
Description: This group will receive laparoscopic-assisted intraperitoneal instillation by using 1 ml/kg of bupivacaine 0.25% with a maximum volume of 20 mL will be instilled into the peritoneal cavity immediately after gas insufflation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: bupivacaine
Study: NCT06443073

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes for speech disorders: positive
Description: The Communicative Participation Item Bank (CPIB) aims to assess communication participation in all kinds of communication disorders. The Voice Self-Efficacy Questionnaire (VSEQ) monitors self-efficacy in individuals with self-declared voice problems before and after interventions. The Vocal Fatigue Handicap Questionnaire (VFHQ) and the Vocal Fatigue Index (VFI) aim at reflecting vocal fatigue. Both have been adapted to reflect purely positive wording.
Study: NCT05902845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD13-02 cell infusion
Description: CAR-T cells
Study: NCT05856084

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose Recombinant Herpes Zoster Vaccine (CHO cells)
Description: 0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with low dose MA105.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose Recombinant Herpes Zoster Vaccine (CHO cells)
Description: 0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with low dose MA105.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose Recombinant Herpes Zoster Vaccine (CHO cells)
Description: 0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with high dose MA105.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose Recombinant Herpes Zoster Vaccine (CHO cells)
Description: 0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with high dose MA105.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive control
Description: 0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with AS01B.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL per dose, containing 4.5 mg sodium chloride.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL per dose, containing 4.5 mg sodium chloride.
Study: NCT06326125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TICK-B
Description: TICK-B as art-based distraction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKTX-Cream
Description: TKTX-Cream as local anesthesia cream

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TICK-B and TKTX-C
Description: TICK-B and TkTx-C as combined intervention approche (pharmacology and non-pharmacology)
Study: NCT06519617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yi Qi Yang Yin Decoction
Description: The Yi Qi Yang Yin Decoction (Dihuang 15g, Baihe 12g, Nanshashen 15g, celery Qinghao 10g, Malt 10g, Shengma 6g, Chaihu 6g) prescription for patients eligible for qi and yin deficiency was 200 ml twice daily for 12 weeks.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Hydroxychloroquine Sulfate
Description: Hydroxychloroquine Sulfate Tablets 200-400mg daily for 12 weeks.
Study: NCT06504420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Subjects will receive Sirolimus 1.5mg/d for 48 weeks in addition to their ongoing APS treatment regimen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive Placebo 1.5mg/d for first 24 weeks and Sirolimus 1.5mg/d for next 24 weeks in addition to their ongoing APS treatment regimen
Study: NCT03465826

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PainCOACH Pain Coping Skills Training
Description: Migraineurs will participate in 4 weeks of daily headache monitoring, baseline questionnaires, followed by 8 weeks of the PainCOACH migraine mHealth Pain Coping Skills Training program (developed by Drs. Keefe and Rini based on social cognitive theory and in-person pain coping therapy sessions). Following the 8 week mHealth intervention, participants will immediately complete post-treatment assessments and later will complete follow-up assessments at 3 and 6 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Participants will keep headache diaries for 4 weeks, followed by baseline assessments + 8 weeks of daily headache monitoring (as a parallel to the PainCOACH intervention). Post-assessments will immediately follow, and participants later will complete follow-up assessments at 3 and 6 months.
Study: NCT04914819

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Behavioral Weight Loss Program
Description: Participants will be enrolled in a 16-week online behavioral weight loss program based on the Diabetes Prevention Program (DPP). The program involves weekly brief videos, a self-monitoring platform, automated feedback, and access to a health coach.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual weigh-in
Description: Participants will be sent a digital scale and will be asked to complete a virtual weigh-in at home at the start of the study and again after 16 weeks.
Study: NCT05328336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab Nab paclitaxel
Description: Drug: Tislelizumab Tislelizumab 200mg will be administered on Day 1 every 3 weeks for 3 cycles~Other Names:~• BGB-A317 Drug: Nab paclitaxel Nab paclitaxel 200mg will
Study: NCT05824416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: ALBA
Description: Device: Improve Upper Limb Mobility~The patients will undergo treatment with the conventional therapy, consisting of four types of exercises, including supine and seated exercises, bimanual seated activity, and bipedal exercise. In addition to training with the ALBA® device, Shoulder flexion, abduction, and external rotation, elbow flexion and extension.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: The conventionl therapy will receive conventional treatment, consisting of four types of exercises, including supine and seated exercises, bimanual seated activity, and bipedal exercise
Study: NCT04914819

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual weigh-in
Description: Participants will be sent a digital scale and will be asked to complete a virtual weigh-in at home at the start of the study and again after 16 weeks.
Study: NCT05047016

Intervention type: OTHER
Group type: OTHER
Intervention: Virtual investigational product
Description: The virtual investigational product is a predefined text (e.g. AB123F). By entering the code into the application, the virtual 'administration' of the IP is conducted.
Study: NCT05104749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homeopathic Medication
Description: Homeopathic medicines are prepared according to standardized methods as specified by the Homeopathic Pharmacopoeia of the United States (HPUS), which was mandated by Congress to regulate the manufacture of homeopathic medicines as part of the Food, Drug, and Cosmetics Act of 1939. All homeopathic medicines prescribed in this study must be found in the HPUS. For a complete list of homeopathic medicines, contact the researchers.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert lactose pellets
Study: NCT05936372

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute intense aerobic exercise
Description: The acute intense aerobic exercise bout (iE) will consist of a 13-minute 20-meter shuttle run. During this exercise bout two speeds, based on a percentage of the estimated maximal oxygen consumption (VO2max), will be combined: a fast-paced speed (fast: 85% of VO2max) and a slow-paced speed (slow: 60% VO2max). A total of 3 series of 3 min of the fast-paced speed will be carried interspersed with 2 series of 2 min of the slow-paced speed. Prior to the iE start, a warm-up protocol consisting of 2 min slow and 1 min fast will be done with the objective to familiarize participants with the iE speeds. A 5-minute rest period will be guaranteed before starting the iE. Transition time between iE and the rotational visuomotor adaptation task (rVMA) will be 4 min.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute intense aerobic exercise
Description: The acute intense aerobic exercise bout (iE) will consist of a 13-minute 20-meter shuttle run. During this exercise bout two speeds, based on a percentage of the estimated maximal oxygen consumption (VO2max), will be combined: a fast-paced speed (fast: 85% of VO2max) and a slow-paced speed (slow: 60% VO2max). A total of 3 series of 3 min of the fast-paced speed will be carried interspersed with 2 series of 2 min of the slow-paced speed. Prior to the iE start, a warm-up protocol consisting of 2 min slow and 1 min fast will be done with the objective to familiarize participants with the iE speeds. A 5-minute rest period will be guaranteed before starting the iE. Transition time between iE and the rotational visuomotor adaptation task (rVMA) will be 4 min.
Study: NCT04816786

Intervention type: OTHER
Intervention: no intervention will be administered, this is a retrospective observational study.
Description: no intervention will be administered, this is a retrospective observational study.

Intervention type: OTHER
Intervention: no intervention will be administered, this is a retrospective observational study.
Description: no intervention will be administered, this is a retrospective observational study.
Study: NCT06059833

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnesium
Description: The aim of the study is to evaluate serum Mg level in type 2 DM patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnesium
Description: The aim of the study is to evaluate serum Mg level in type 2 DM patients.
Study: NCT05484219

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional navigation
Description: Surgeon removes brain tumor or vascular malformation and assesses location of motor areas with functional navigation and intraoperative neuromonitoring
Study: NCT06044012

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double layer of buccal myomucosal Flap and buccal pad of fat
Description: The buccal myomucosal flap will be harvested from cheek below stenson papilla and will be sutured over buccal pad of fat which will be sutured at palatal mucosa after complete curettage of infected fistulous tract.
Study: NCT05416697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD oil
Description: The subjects will receive cannabis 2.7 mg THC 2.5 mg CBD twice daily (1 droplet twice daily; 0.73 mg THC and 0.81 mg CBD/drop, 1.46 mg THC and 1.62 CBD/day) for 1 week then titrate up to 2 droplets twice daily if tolerated (2.92 mg THC and 3.24 CBD per day) and continue the treatment until the end of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects will receive 1 droplet of placebo twice daily then titrate up to 2 droplets twice daily if tolerated and continue the treatment until the end of the study.
Study: NCT06372327

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Exercise Snacks
Description: Participants will be encouraged to break up prolonged sitting at work with brief, high-intensity exercise snacks of varying length / total number depending on condition assignment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Exercise Snacks
Description: Participants will be encouraged to break up prolonged sitting at work with brief, high-intensity exercise snacks of varying length / total number depending on condition assignment.
Study: NCT04680845

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-affirmation
Description: According to self-affirmation theory (Steele, 1988), defensiveness arises because people are motivated to defend their global sense of self-worth, which in the present case is threatened by perceptions of hearing aids/loss. However, if a person's self-image can be bolstered (affirmed) in a domain that is important to them, thereby preserving self-integrity, the individual should be less likely to process the threatening (i.e., stigmatizing in the present context) information defensively (Steele, 1988).
Study: NCT05657392

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Repetitive Transcranial Magnetic Stimulation (rTMS) is a noninvasive intervention that uses magnetic fields to stimulate nerve cells to improve the symptoms of a variety of disorders, including stroke-related motor impairment. Last few decades, it has been revealed that rTMS accelerates motor recovery and may reduce stroke-related symptoms.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 32 electrode electroencephalography (EEG)
Description: 32-electrode EEG will be non-invasively recorded from electrodes placed in a montage over the scalp while the participant is resting
Study: NCT06041191

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment
Description: The children included in the study were evaluated in terms of hypermobility and then divided into two groups. Children in both groups were evaluated in terms of sensory processing skills.

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment
Description: The children included in the study were evaluated in terms of hypermobility and then divided into two groups. Children in both groups were evaluated in terms of sensory processing skills.
Study: NCT04921488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: screening colonoscopy
Description: The screening colonoscopy will be performed by an investigator. The automatic detection and characterization system will be activated at the time of descent of the colonoscopy (after caecal intubation), with video recording (image without CAD EYE and image with CAD EYE). The investigator performing the colonoscopy will be blinded by the results of the CAD EYE.
Study: NCT04140474

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Archimedes procedure
Description: All patients will initially have a scanner necessary for planning by the Archimedes system of the tunneling path. each patient will then undergo a general anesthesia as for any bronchoscopy. Then start the Archimedes procedure itself to reach the SPN
Study: NCT05431738

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gastroesophageal stent placement
Description: A gastroesophageal stent is placed during a digestive endoscopy performed under general anesthesia, under endoscopic and fluoroscopic control

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gastroesophageal stent placement
Description: A gastroesophageal stent is placed during a digestive endoscopy performed under general anesthesia, under endoscopic and fluoroscopic control
Study: NCT05903378

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relational touch practice
Description: Relational touch practice during the first bedside session. Touch in care aims to improve the patient's perception of potentially painful or anxiety-provoking acts of care. It is based on techniques of skin contact, developing and deepening.
Study: NCT05838820

Intervention type: DIAGNOSTIC_TEST
Intervention: Nine-Hole Peg Test
Description: The Nine-Hole Peg Test is a standardized test that measures manual dexterity and finger movement speed in individuals with hand impairments. The test involves the placement of nine pegs in a pegboard, one at a time, and then removal of each peg as quickly as possible using one hand. The test is timed, and the time required to complete the test provides an indication of manual dexterity and finger movement speed. The Nine-Hole Peg Test has been previously validated and is commonly used in clinical practice.

Intervention type: DIAGNOSTIC_TEST
Intervention: Jebsen-Taylor Hand Function Test
Description: is a standardized test that assesses fine motor skills and functional abilities of the hand. The test involves the completion of seven subtests, including writing, simulated page turning, picking up small objects, stacking checkers, lifting large objects, simulated feeding, and stacking cans. Each subtest is timed, and the time required to complete each subtest provides an indication of hand function. The Jebsen-Taylor Hand Function Test has been previously validated and is commonly used in clinical practice.
Study: NCT05501457

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Muscle strengthening with neuromuscular electrical stimulation
Description: The effect of peripheral muscle strengthening training in addition to pulmonary rehabilitation in COPD patients on the patient's performance will be examined.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Muscle strengthening with neuromuscular electrical stimulation
Description: The effect of peripheral muscle strengthening training in addition to pulmonary rehabilitation in COPD patients on the patient's performance will be examined.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Muscle strengthening with neuromuscular electrical stimulation
Description: The effect of peripheral muscle strengthening training in addition to pulmonary rehabilitation in COPD patients on the patient's performance will be examined.